Loading...
XLON
HIK
Market cap4.55bUSD
Oct 07, Last price  
1,646.00GBP
1D
1.60%
1Q
1.92%
Jan 2017
-13.05%
IPO
483.69%
Name

Hikma Pharmaceuticals PLC

Chart & performance

D1W1MN
XLON:HIK chart
P/E
11.09
P/S
1.36
EPS
1.96
Div yield, %
3.86%
Shrs. gr., 5y
-1.32%
Rev. gr., 5y
7.42%
Revenues
3.35b
+7.10%
317,022,000448,796,000580,656,000636,884,000730,936,000918,025,0001,109,000,0001,365,000,0001,489,000,0001,440,000,0001,950,000,0001,936,000,0002,070,000,0002,207,000,0002,341,000,0002,553,000,0002,517,000,0002,875,000,0003,127,000,0003,349,000,000
Net income
410m
+14.33%
54,522,00062,576,00057,125,00077,683,00098,849,00080,107,000100,000,000212,000,000278,000,000252,000,000155,000,000-843,000,000282,000,000486,000,000431,000,000421,000,000188,000,000190,000,000359,000,000410,434,081
CFO
367m
-35.01%
29,992,00043,117,00057,872,000105,518,000138,786,000102,639,000182,161,000337,000,000425,000,000366,000,000293,000,000443,000,000430,000,000472,000,000464,000,000638,000,000530,000,000608,000,000564,000,000366,531,928
Dividend
Aug 13, 202628.136 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.

Related entities

Subsidiaries
HIKMA VENTURES LIMITED

Key people

Executive Chairman of the Board · since 2018
Brian Hoffman
President, US Generics Division · since 2017
Riad Mishlawi
President - Injectables · since 2018
Majda Labadi
Executive Vice President - Organisational Development · since 2018
Henriette Nielsen
Executive Vice President - Business Operations · since 2018
Susan Ringdal
Executive Vice President - Strategic Planning and Global Affairs and Investor Relations · since 2018
Khalid Nabilsi
Chief Financial Officer, Executive Director · since 2011
Peter Speirs
Company Secretary · since 2012
Ali K. Al-Husry
Non-Executive Director · since 2005
Jochen Gann
Non-Executive Director · since 2015
John J Castellani
Non-Executive Independent Director · since 2016
Non-Executive Independent Director · since 2019
IPO date
Nov 01, 2005
Employees
8,700
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
1 New Burlington Place
London, LND W1S 2HR
GB
Previous name
HIKMA PHARMACEUTICALS PLC
Previous name
HIKMA PHARMA PUBLIC LIMITED COMPANY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT